Overall verdict
Neutral
6.1/10
1-year performance
+17.81%
Score breakdown
Up 17.8% over 1 year, 60% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Valuation 1.7/10.
29 analysts, target +0.2% vs the price.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Bernard Zovighian
Founded
1958
Employees
16 000
Revenue / employee
379 225 USD
Next earnings
October 23, 2026 (estimated)
Institutional holders
- BlackRock, Inc.10.19%
- VANGUARD CAPITAL MANAGEMENT LLC6.52%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.58%
- STATE STREET CORP4.56%
- JPMORGAN CHASE & CO3.95%
- WELLINGTON MANAGEMENT GROUP LLP2.92%
- GEODE CAPITAL MANAGEMENT, LLC2.68%
- Bank of New York Mellon Corp2.44%
- DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main2.25%
- Other institutions50.37%
- Rest of the register9.55%
1330 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
96.29 USD
52-week low
72.30 USD
1-year performance
17.81%
Rising
Year-to-date performance
1.59%
Rising
Drawdown
-9.92%
Mild pullback
Position in the 52-week range
60% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.5 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Edwards Lifesciences | 195 823 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.5 times as much as the world ETF.
- Worst fall:-53 % between April 2022 and July 2024. 10,000 € placed at the top fell to 4 653 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Edwards Lifesciences earned 3 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Edwards Lifesciences: 195 823 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 45.80 USD - 49.06 USD (2 methods agree)
The price implies growth of 12.28% per year; the company grows at 6.79%.
Gross margin 78.3%, net margin 15.0%, ROIC 8.7%, ROE 9.3%.
Net margin
15.05%
Exceptional
Sector 8.18%|S&P 12.97%
Gross margin
78.28%
High
Return on equity (ROE)
9.26%
High
Sector 6.97%|S&P 16.52%
Return on invested capital (ROIC)
8.70%
Exceptional
Free cash flow margin (FCF)
22.01%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.46x
High
Margin stability
17.0 pts
Very uneven
Revenue to net income
Growth
2.5/10Revenue up 13.6% over 1 year, 6.7% a year over 5, EPS 6.8% a year over 5.
Revenue (trailing 12 months)
6.5Md USD
Revenue growth (1y)
13.63%
Hyper-growth
Revenue growth (3y)
12.73%
Moderate
EPS growth (1y)
-27.06%
Declining
EPS CAGR (5y)
6.79%
Low
EPS revisions (3 months)
-0.27%
Revised down
Valuation
1.7/10P/E 51.5x, forward P/E 34.3x, EV/EBITDA 29.6x, PEG 7.58. The multiple sits in the 84th percentile of its own 5-year history.
P/E (TTM)
51.5x
Expensive
Sector 28.9x|S&P 23.0x
Forward P/E
34.3x
Expensive
EV / EBITDA
29.6x
Expensive
Sector 15.7x|S&P 14.5x
PEG
7.58
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
47.43 USD
Deeply overvalued
P/E vs its own 5-year history
among the 16% highest valuations
At its historical high
Market cap
50.0Md USD
Financial strength
10.0/10Cash covers 604.1% of the debt, net debt/EBITDA -2.0x.
Net debt / EBITDA
-2.0x
Net cash
Gearing (net debt / equity)
-33.11%
Net cash
Cash
4.3Md USD
Cash / market cap
8.50%
Solid
Cash / total debt
604.07%
Net cash
Interest coverage
69.7x
Very solid
Net debt
-3.6Md USD
Equity
10.7Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 85.73 USD
- MM2088.15
- MM5088.35
- MM20085.05
- RSI 1440.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.39%
200-day average slope, 3 months
+3.59%
50-day average slope, 1 month
-0.95%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.57 % per day
Volatility change
-1.33%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.53 (10) | 3.00 (28) | 6 760 (28) | 2 137 (17) | 1 435 (8) |
| 2027 | 3.30 (10) | 3.38 (28) | 7 429 (28) | 2 384 (18) | 1 897 (9) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 21, 2026.
Same sub-industry: 190 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BSX | 7.0 | 7.2 | 64.7Md USD | 18.1x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -54.3 % | ||
| 2 | MDT | 6.9 | 6.9 | 114Md USD | 22.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -6.7 % | ||
| 3 | SYK | 6.9 | 7.5 | 105Md USD | 28.3x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -27.6 % | ||
| 4 | ABT | 6.6 | 6.3 | 179Md USD | 33.5x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -25.3 % | ||
| 5 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -11.4 % | ||
| 6 | IDXX | 6.3 | 6.4 | 41.1Md USD | 36.7x | 25.0 % | 9.7 % | 56.6 % | 0.5x | 3.0 % | -20.4 % | ||
| 7 | SHL | 6.3 | 6.5 | 47.2Md USD | 18.9x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -20.5 % | ||
| 8 | EW | 6.1 | 5.1 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 17.8 % | ||
| 9 | BDX | 5.7 | 5.1 | 49.7Md USD | 55.1x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 22.7 % |
